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ORIGINAL ARTICLE
Background/Aims: Hepatitis C virus (HCV) RNA testing can be performed using qualitative or quantitative
assays, and it is still unclear which is more useful as a primary test in patients positive for anti-HCV. The present
study evaluated the usefulness of anti-HCV signal-to-cutoff ratio (S/CO ratio) for predicting HCV RNA results.
Methods: Patients on whom a qualitative HCV RNA test was performed due to a positive anti-HCV enzyme
immunoassay were enrolled. Patients were divided into viremia and no-viremia groups according to HCV RNA
results. Receiver-operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic
accuracy of anti-HCV S/CO for a diagnosis of viremia.
Results: In total, 487 patients were enrolled. HCV RNA was positive in 301 subjects (61.8%). Age, serum ALT
level, and anti-HCV S/CO ratio were significantly different between the viremia and no-viremia groups. By ROC
curve analysis, anti-HCV S/CO ratio (area, 0.989; 95% confidence interval, 0.981 to 0.998) accurately predicted
the presence of viremia, with a cutoff value of 10.9 (sensitivity, 94.4%; specificity, 97.3%).
Conclusions: Anti-HCV S/CO ratio was found to be highly accurate at predicting HCV viremia. The anti-HCV
S/CO ratio can be used to determine whether a quantitative or qualitative HCV RNA test should be used to
confirm HCV viremia in patients with a positive anti-HCV by the following criteria: if the anti-HCV S/CO ratio is
<10.9, a qualitative HCV RNA test can be used, and if the anti-HCV S/CO ratio is ≥10.9 a quantitative HCV RNA
test can be performed. (Korean J Intern Med 2009;24:302-308)
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INTRODUCTION
Hepatitis C virus (HCV) is a major public health problem
and one of the leading causes of death from liver disease
[1]. According to the World Health Organization, approxi-
mately 3% of the world’s population is infected with HCV
[2]. In Korea, anti-HCV is positive in 0.4-2.1% of the
general population [3,4]. Furthermore, because chronic
HCV infection is a leading cause of chronic hepatitis, liver
cirrhosis, and hepatocellular carcinoma [1], precise
detection of HCV viremia is of considerable importance.
The usual screening approach to detect HCV infection
involves initial testing for antibodies to HCV (anti-HCV)
[1]. However, although anti-HCV assays are highly sensitive
and specific for detecting patients with a chronic HCV
infection [5], false positive results are not infrequent,
especially in low-risk populations (with an anti-HCV
prevalence of <10%) [6,7]. Therefore, HCV RNA testing
(qualitative or quantitative) is recommended in those
with positive anti-HCV findings [6]. However, whether
qualitative or quantitative HCV RNA testing is more
useful in confirming HCV viremia in patients positive for
anti-HCV remains a matter of debate. Some experts prefer
quantitative HCV RNA testing because most cases with anSeo YS, et al. Anti-HCV signal-to-cutoff ratio    303
ongoing HCV infection have HCV RNA levels that are
detected by quantitative assays and because knowing HCV
RNA amounts before providing and monitoring HCV
treatment is useful [8]. However, because quantitative
HCV RNA tests are generally less sensitive and more
expensive than qualitative tests, some experts prefer a
qualitative HCV RNA test as the primary test [9,10].
Recent studies have suggested that a high anti-HCV
titer favors the presence of viremia. An anti-HCV signal-
to-cutoff (S/CO) ratio of ≥3.8 was found to predict a true
positive in ≥95% of cases when Abbott second-generation
HCV EIA or Ortho third-generation HCV kits were used
[6]. Furthermore, the US Centers for Disease Control and
Prevention suggested that anti-HCV S/CO ratios can be
used to determine the need for supplementary testing [6].
This retrospective study was performed to evaluate the
usefulness of anti-HCV S/CO ratios for predicting HCV
RNA viremia in patients with a positive anti-HCV finding.
We also evaluated the usefulness of the anti-HCV S/CO
ratio in predicting falsepositive results in anti-HCV in
patients positive for anti-HCV, but negative for HCV RNA.
METHODS
Patients
All patients who underwent a HCV RNA qualitative
assay because of a positive anti-HCV test between August
2006 and April 2008 were enrolled. Patients who had
previously been treated with interferon or pegylated
interferon, those previously diagnosed as having chronic
hepatitis C, liver cirrhosis, or hepatocellular carcinoma,
those with a serum alanine aminotransferase (ALT) level
at more than 10 times the upper limit of normal (i.e.,
≥400 IU/L), and those with a positive hepatitis B surface
antigen or positive anti-HIV finding were excluded.
All included patients were allocated to one of two groups
according to the results of qualitative HCV RNA testing:
patients positive for HCV RNA to the viremia group, and
patients negative for HCV RNA to the no-viremia group.
Patients positive for anti-HCV and negative for HCV RNA
were classified into two groups, according to recombinant
immunoblot assay (RIBA) findings: patients positive by
RIBA were allocated to the past-exposure group, and
patients negative by RIBA to the false-positive group.
Table 1. Baseline characteristics of the patients according to the HCV RNA
All patients  Viremia group* No-viremia group† p value 
(n=487) (n=301) (n=186)
Male, n (%) 230 (47.2) 135 (44.9) 95 (51.1) 0.181
Age, yr 56±16 58±14 53±18 0.002
ALT, IU/L 49±49 62±55 27±26 <0.001
Anti-HCV S/CO ratio 10.1±5.6 14.0±2.0 3.7±3.1 <0.001
HCV, hepatitis C virus; ALT, alanine aminotransferase; S/CO ratio, signal to cutoff ratio.
*Patients positive for HCV RNA.
†Patients negative for HCV RNA. 
Figure 1. Age, serum ALT level, and anti-HCV S/CO according to qualitative HCV RNA test results. 
Box, range from 25th to 75th percentile; the line at the middle of the box, median value; error bar, range from lowest to highest values.
Viremia group, patients positive for HCV RNA; No-viremia group, patients negative for HCV RNA. 
ALT, alanine aminotransferase; HCV, hepatitis C virus; S/CO ratio, signal-to-cutoff ratio.304 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
Laboratory tests
Hepatitis C screening was performed using an anti-
HCV enzyme immunoassay (Architect i2000; Abbott
Laboratories, Abbott Park, IL, USA). Results are reported
using S/CO ratios; anti-HCV was considered positive
when the S/CO ratio was greater than 1. Serum ALT levels
were checked at the same time, and ALT was considered
abnormal when its level was greater than 40 IU/L.
HCV RNA qualitative assays (Cobas Amplicor; Roche,
Basel, Switzerland; lower detection limit, 50 IU/mL) were
performed on patients with positive anti-HCV tests. HCV
RNA quantitative assays (Cobas TaqMan Analyzer;
Roche; lower detection limit, 15 IU/mL) and HCV
genotype testing were performed on patients with HCV
viremia. In patients without viremia, recombinant
immunoblot assays (RIBA; MPD HCV Blot 3.0; MP
Diagnostics, Science Park, Singapore) were performed.
When both HCV RNA and RIBA were negative, positive
anti-HCV results were considered false positives.
RIBA was performed using the Chiron RIBA HCV 3.0
Strip Immunoblot Assay (Chiron Co., Emeryville, CA,
USA) according to the manufacturer’s protocol. This assay
detects antibodies directed to both structural antigens
(core antigen and c22 synthetic peptide) and non-
structural antigens (NS3 antigen, c33c recombinant
protein; NS4 antigen, mixed 5.1.1 and c100 peptides; NS5
antigen, recombinant protein). For this assay, the
intensities of colored bands on a nitrocellulose strip are
proportional to amounts of bound antibody and are
graded as negative, 1+, 2+, 3+, and 4+, according to the
manufacturer’s instructions. The minimum requirement
for a positive result is two HCV-specific bands with
reactivities of at least 1+. An indeterminate result was
defined as: 1) one HCV-specific band with a reactivity of
≤1+ or 2) a reactivity of at least 1+ to human superoxide
dismutases and one or more HCV-specific bands. A negative
result was defined as the absence of a HCV-specific band
of reactivity ≥1+.
Statistics
Statistical analysis was carried using the SPSS version
10.0 (SPSS Inc., Chicage, IL, USA). Quantitative variables
are expressed as mean values±standard deviations (SD).
Differences between continuous variables were assessed
using Student’s t-test. Binary regression analyses were
used to identify significant predictors of HCV viremia.
Spearman’s correlation coefficients were used to analyze
the correlation between anti-HCV S/CO ratios and
HCV RNA levels. Multivariate regression analysis was
performed to evaluate the significant predictive factors for
HCV viremia or for RIBA results. Receiver-operating
characteristics (ROC) curve analysis was performed to
evaluate the predictive accuracy of anti-HCV S/CO for
the diagnosis of viremia and false-positive reactivity.
The Hanley-McNeil test was used to compare area under
ROC curves (AUROCs) [11]. Two-tailed p values of <0.05
were deemed to be statistically significant.
Table 2. Multivariate regression analysis for the prediction of HCV viremia
p value β Odds ratio 95% Confidence interval
Sex 0.291
Age 0.016 0.043 1.044 1.008-1.082
ALT level <0.001 0.032 1.033 1.015-1.051
Anti-HCV S/CO ratio <0.001 1.059 2.883 2.188-3.799
HCV, hepatitis C virus; ALT, alanine aminotransferase; S/CO ratio, signal to cutoff ratio.
Figure 2. Receiver-operating characteristic curve of anti-HCV
S/CO ratio for predicting the results of qualitative HCV RNA
testing in 487 patients positive for anti-HCV.
HCV, hepatitis C virus; S/CO ratio, signal-to-cutoff ratio; ALT,
alanine aminotransferase.Seo YS, et al. Anti-HCV signal-to-cutoff ratio    305
RESULTS
Anti-HCV S/CO ratio vs. HCV viremia
During the study period, 661 patients were positive for
anti-HCV, and HCV RNA tests were performed in 487
patients (73.7%). The mean age of the 487 patients was 56
years (SD, 16 years), and 230 patients were males (47.2%).
The mean serum ALT level and the anti-HCV S/CO ratio
were 49±49 IU/L and 10.1±5.6, respectively (Table 1).
HCV viremia was present in 301 patients (61.8%) by
qualitative HCV RNA testing. Age, serum ALT level, and
anti-HCV S/CO ratio were significantly different in the
viremia and no-viremia groups (Fig. 1). Serum ALT level
was above the upper normal limit (i.e., >40 IU/L) in 167
(55.5%) of the 301 patients in the viremia group and in 26
(14.0%) of the 186 patients in the no-viremia group
(p<0.001). Age, serum ALT level, and anti-HCV S/CO
ratio were significant predictive factors of HCV viremia
by multivariate regression analysis (Table 2).
Anti-HCV S/CO ratio (area, 0.989; 95% confidence
interval [CI], 0.981 to 0.998) was more accurate than age
(area, 0.574; 95% CI, 0.520 to 0.628) or ALT level
(area,0.774; 95% CI, 0.732 to 0.816) in predicting the
presence of viremia by ROC curve analysis (Fig. 2). Using
an anti-HCV S/CO ratio cutoff value of 10.9, sensitivity,
specificity, positive predictive value, and negative
predictive value for HCV viremia were 94.4%, 97.3%,
98.3%, and 91.4%, respectively (Table 3). All patients with
an anti-HCV S/CO ratio of <4.4 (138 patients, 28.3%)
were negative for HCV RNA, and all patients with an anti-
HCV S/CO ratio >14.4 (127, 26.1%) were positive.
A HCV RNA quantitative assay was performed on 250
Table 3. Predictive accuracies of age, serum ALT level, and anti-HCV S/CO ratio for HCV viremia
Age ALT Anti-HCV S/CO ratio
AUROC (95% CI) 0.574 (0.520-0.628) 0.774 (0.732-0.816) 0.989 (0.981-0.998)
Cutoff value 44.5 yr 32.5 IU/L 10.9
Sensitivity 81.3% 66.3% 94.4%
Specificity 32.8% 77.4% 97.3%
PPV 66.2% 82.6% 98.3%
NPV 52.1% 58.8% 91.4%
ALT, alanine aminotransferase; HCV, hepatitis C virus; S/CO ratio, signal to cutoff ratio; AUROC, area under the receiver-operating characteristics
curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.
Figure 3. Scatter plots of anti-HCV S/CO ratio against HCV
RNA levels as determined by qualitative HCV RNA testing.
HCV, hepatitis C virus; S/CO ratio, signal-to-cutoff ratio.
Table 4. Baseline characteristics of patients positive for HCV RNA according to HCV genotype
Patients with genotype 1 Patients with genotype 2 p value
(n=83) (n=96)
Male, n (%) 39 (47.0) 43 (45.0) 0.769
Age, yr 53±14 56±14 0.261
ALT, IU/L 79±54 67±67 0.221
Anti-HCV S/CO ratio 14.4±2.1 14.0±1.8 0.222
HCV RNA, log10 IU/mL 6.3±0.8 5.6±0.9 <0.001
HCV, hepatitis C virus; ALT, alanine aminotransferase; S/CO ratio, signal to cutoff ratio.306 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
(83.1%) of the 301 patients in the viremia group, and no
correlation was found between anti-HCV S/CO ratio and
HCV RNA level (Spearman’s correlation coefficient,
0.037; p=0.564; Fig. 3). HCV genotype analysis was
performed in 179 patients (59.5%). Of them, 83 patients
(46.4%) were of genotype 1, and 96 (53.6%) were of
genotype 2. Although HCV RNA level was higher in
patients with genotype 1, age, gender, serum ALT, and
anti-HCV S/CO ratio were not different between patients
with these genotypes (Table 4).
Anti-HCV S/CO ratio in patients without HCV
viremia
RIBA was performed in 87 of the 186 patients in the no-
viremia group (46.8%), and results were positive in 41
patients (past-exposure group, 48.2%), negative in 44
patients (false-positive group, 51.8%), and indeterminate
in two (2.3%). Mean ALT level and anti-HCV S/CO ratio
differed in the past-exposure and false-positive groups
(Table 5). However, multivariate regression analysis
indicated that only the anti-HCV S/CO ratio significantly
predicted RIBA results (OR, 1.771; 95% CI, 1.299 to
2.414; p<0.001).
AUROC of anti-HCV S/CO ratio for false-positive anti-
HCV tests was 0.792 (95% CI, 0.690 to 0.894; Fig. 4). At
an anti-HCV S/CO-ratio cutoff value of 2.5, sensitivity,
specificity, PPV, and NPV were 73.2%, 81.8%, 78.4%, and
75.0%, respectively.
DISCUSSION
Positive anti-HCV may represent current active infection
with HCV viremia, past exposure to HCV, or false-positive
reactivity. The HCV RNA test is considered the gold
standard to confirm the presence of HCV viremia, but
whether quantitative or qualitative HCV RNA testing is
the more useful initial confirmatory test in patients
positive for anti-HCV has not been resolved.
Qualitative tests are generally more sensitive than
quantitative tests at determining the presence or absence
of the virus, whereas quantitative tests are more useful
for monitoring antiviral therapy and must be performed
before therapy is started [12]. Thus, if the result of a
qualitative HCV RNA test is positive in patients scheduled
for antiviral therapy, blood sampling must be repeated
for quantitative HCV RNA testing, which consumes time
and money. On the other hand, quantitative HCV RNA
testing in patients without viremia also increases costs
without gain. Thus, if we could better predict the result of
HCV RNA testing, savings in cost and time could be
achieved.
According to our results, the anti-HCV S/CO ratio
accurately predicts HCV viremia in patients positive for
anti-HCV. At an anti-HCV S/CO ratio cutoff value of 10.9,
sensitivity and specificity were high, 94.4% and 97.3%,
respectively. Furthermore, these results are consistent
Table 5. Baseline characteristics of patients negative for HCV RNA according to RIBA results
Patients with negative RIBA  Patients with positive RIBA p value
(n=41) (n=44)
Male, n (%) 22 (47.8) 18 (40.9) 0.574
Age, yr 51±18 53±16 0.568
ALT, IU/L 21±11 30±25 0.039
Anti-HCV S/CO ratio 2.0±1.5 4.9±3.2 <0.001
HCV, hepatitis C virus; RIBA, recombinant immunoblot assay; ALT, alanine aminotransferase; S/CO ratio, signal to cutoff ratio.
Figure 4. Receiver-operating characteristic curve of anti-HCV
S/CO ratio for predicting RIBA results in 85 patients positive
for anti-HCV and negative by qualitative HCV RNA assay.
HCV, hepatitis C virus; S/CO ratio, signal-to-cutoff ratio; RIBA,
recombinant immunoblot assay.Seo YS, et al. Anti-HCV signal-to-cutoff ratio    307
with those of several previous studies [13-19]. A recent
study found no correlation between the anti-HCV S/CO
ratio and the degree of liver damage [13]. Patients with
liver decompensation had higher S/CO ratios than did
asymptomatic patients, but this difference did not remain
after considering viremia patients with and those without
liver decompensation [13]. Accordingly, in this previous
study it was suggested that the S/CO ratio was more
related to the presence of HCV RNA in serum than with
the severity of liver disease [13].
Actually, the proportion of patients with HCV viremia
among patients with positive anti-HCV could be signifi-
cantly different among study groups, depending on the
inclusion and exclusion criteria. For example, the
proportion of patients with HCV viremia would be much
higher in patients with chronic hepatitis than in patients
with positive anti-HCV at a general health check-up. In
this study, patients with already known chronic liver
diseases were excluded. Thus, our data might be applicable
to patients who have no history of chronic hepatitis but
who are unexpectedly found to be positive when given the
anti-HCV test at their general health check-up.
Because anti-HCV is produced by antigen stimulation
secondary to viral replication, anti-HCV antibody levels
appear to be increased when viral stimulation is high.
Thus, the anti-HCV S/CO ratio is likely to be higher in
patients with HCV viremia, in whom viral stimulation is
strong and continuous, than in patients with a history of
infection or with a waning infection [17].
The high accuracy of the anti-HCV S/CO ratio for
predicting the presence of HCV viremia found in the
present study could be used to determine the type of
HCV RNA test that should be used in patients positive
for anti-HCV. Because the possibility of HCV viremia is
low in patients with an anti-HCV S/CO ratio of <10.9,
qualitative HCV RNA testing is recommended in such
patients. On the other hand, quantitative HCV RNA testing
could be adopted in patients with an anti-HCV S/CO ratio
of >10.9 because most of these patients do have HCV
viremia (98.3%), and quantitative measures of HCV RNA
should be administered in these patients before treatment.
Although anti-HCV S/CO ratios were significantly
different in the past-exposure and false-positive groups,
the anti-HCV S/CO ratio was less helpful in predicting
RIBA results in patients without HCV viremia. This result
is probably explained by changes in the anti-HCV S/CO
ratio in those with a history of exposure. Recent studies
suggest that anti-HCV titers decline in subjects who
experience spontaneous resolution of infection [20,21].
Additionally, patients with chronic HCV infection who
are clear of the virus after interferon therapy also show
a gradual decline in anti-HCV titer [22]. For this reason,
a recent study suggested that no conclusion can be drawn
when an anti-HCV titer is low, because titers can decrease
gradually after spontaneous resolution [9].
In this study, HCV RNA quantitative tests were
performed only in patients with HCV viremia (positive for
HCV RNA qualitative test), although HCV RNA qualitative
tests were performed in all enrolled patients. However,
the lower detection limit of the HCV qualitative test (50
IU/mL) is somewhat higher than that of HCV RNA
quantitative test (15 IU/mL). Thus, patients with very
low level of HCV viremia (15 to 50 IU/mL) may have been
misclassified into the no-viremia group in this study, and
this potential misclassification could have influenced
the results.
In conclusion, the present study shows that the anti-
HCV S/CO ratio is significantly dependent on the presence
HCV viremia and that it is highly accurate at predicting
the presence of HCV viremia. Furthermore, the type of
HCV RNA test used to confirm the presence of HCV viremia
in anti-HCV positive patients can be determined using the
following: an anti-HCV S/CO ratio <10.9 requires
qualitative HCV RNA testing, and an antiHCV S/CO ratio
≥10.9 requires quantitative HCV RNA testing. 
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